Quantitative estimation of drugs for erectile dysfunction and benign prostatic hyperplasia by high performance liquid chromatography: a review
Abstract
This review article explores the critical application of High-Performance Liquid Chromatography (HPLC) in analyzing medications for Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH). HPLC is essential for the precise measurement of these drugs, whether assessed individually or within combination therapies. The review thoroughly examines various HPLC methodologies, encompassing both single-drug and simultaneous analysis techniques. It addresses the optimization of HPLC conditions and validation practices necessary for achieving reliable results. Key challenges in HPLC analysis are highlighted, including sensitivity issues and the need for specific adjustments in analytical procedures. The article discusses the influence of factors such as column types, mobile phases, and detection methods on HPLC performance. It offers detailed insights into optimizing parameters to enhance resolution and accuracy, providing practical guidance for researchers working with ED and BPH drugs. Moreover, the review outlines best practices for validating HPLC methods according to regulatory standards, which are crucial for maintaining the quality and reproducibility of analytical results. It also identifies potential areas for improvement, including enhancing method sensitivity and reducing analysis time. By emphasizing the importance of HPLC in maintaining high analytical standards for ED and BPH drug analysis, this review serves as a valuable resource for researchers, clinicians,…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.